CG Oncology, Inc. Accounts Payable and Other Accrued Liabilities, Current
CG Oncology, Inc. (CGON) had Accounts Payable and Other Accrued Liabilities, Current of $11.33 million as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2024-11-12
- 2024-09-30: Accounts Payable and Other Accrued Liabilities, Current $11.33M.
- 2024-06-30: Accounts Payable and Other Accrued Liabilities, Current $7.13M.
- 2024-03-31: Accounts Payable and Other Accrued Liabilities, Current $5.11M.
- 2023-12-31: Accounts Payable and Other Accrued Liabilities, Current $10.44M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current |
|---|---|
| 2024-09-30 | $11.33M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $7.13M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $5.11M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $10.44M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |